William C Vesperman

Array ( [id] => 17342090 [patent_doc_number] => 20220008421 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-13 [patent_title] => TREATMENT OF CANCER BY COMBINATION OF IMMUNE CHECKPOINT INHIBITOR AND FOLFIRINOX THERAPY [patent_app_type] => utility [patent_app_number] => 17/297339 [patent_app_country] => US [patent_app_date] => 2019-11-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11362 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17297339 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17792112 [patent_doc_number] => 20220251203 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-11 [patent_title] => USE OF ANTI-PD-1 ANTIBODY IN COMBINATION WITH FAMITINIB IN PREPARATION OF DRUG FOR TREATING TUMORS [patent_app_type] => utility [patent_app_number] => 17/288894 [patent_app_country] => US [patent_app_date] => 2019-11-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7928 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17288894 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17314509 [patent_doc_number] => 20210403557 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-30 [patent_title] => DOSING REGIMEN OF ANTI-TIGIT ANTIBODY FOR TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 17/288641 [patent_app_country] => US [patent_app_date] => 2019-11-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25557 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17288641 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17200182 [patent_doc_number] => 20210340277 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-04 [patent_title] => ANTIBODY COMPOUNDS WITH REACTIVE ARGININE AND RELATED ANTIBODY DRUG CONJUGATES [patent_app_type] => utility [patent_app_number] => 17/284192 [patent_app_country] => US [patent_app_date] => 2019-10-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25077 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -36 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17284192 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17426878 [patent_doc_number] => 20220054586 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-24 [patent_title] => LIQUID COMPOSITION COMPRISING PROTEIN [patent_app_type] => utility [patent_app_number] => 17/274834 [patent_app_country] => US [patent_app_date] => 2019-09-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7619 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17274834 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17156157 [patent_doc_number] => 20210317208 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-14 [patent_title] => ANTI-CD33 ANTIBODIES AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/272083 [patent_app_country] => US [patent_app_date] => 2019-08-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 77434 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -55 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17272083 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18995945 [patent_doc_number] => 11912772 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-02-27 [patent_title] => Anti-galectin-9 antibody and methods of use thereof [patent_app_type] => utility [patent_app_number] => 17/260077 [patent_app_country] => US [patent_app_date] => 2019-07-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 5 [patent_no_of_words] => 14638 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 79 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17260077 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17067314 [patent_doc_number] => 20210269529 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-02 [patent_title] => ANTIBODY INDUCING IMMUNE TOLERANCE, INDUCED LYMPHOCYTE, AND CELL THERAPY AGENT THERAPEUTIC METHOD USING INDUCED LYMPHOCYTE [patent_app_type] => utility [patent_app_number] => 17/254006 [patent_app_country] => US [patent_app_date] => 2019-06-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23694 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17254006 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17008541 [patent_doc_number] => 20210239702 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-05 [patent_title] => METHODS FOR PREDICTING RESPONSIVENESS OF LUNG CANCER PATIENTS TO HER2-TARGETING THERAPIES [patent_app_type] => utility [patent_app_number] => 17/251425 [patent_app_country] => US [patent_app_date] => 2019-06-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13941 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17251425 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16778056 [patent_doc_number] => 20210115134 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-22 [patent_title] => ANTIBODY BINDING SPECIFICALLY TO ECL-2 OF CLAUDIN 3, FRAGMENT THEREOF, AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/042374 [patent_app_country] => US [patent_app_date] => 2019-03-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20597 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17042374 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16482434 [patent_doc_number] => 20200376034 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-03 [patent_title] => ANTIBODY VARIABLE DOMAINS TARGETING CD33, AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/971098 [patent_app_country] => US [patent_app_date] => 2019-02-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 114079 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -154 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16971098 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17428428 [patent_doc_number] => 20220056136 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-24 [patent_title] => ANTI-PD-L1/ANTI-4-1BB BISPECIFIC ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/298741 [patent_app_country] => US [patent_app_date] => 2019-02-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23267 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17298741 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16419835 [patent_doc_number] => 20200345033 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-05 [patent_title] => TREATMENT AND PREVENTION OF SEED ALLERGIES [patent_app_type] => utility [patent_app_number] => 16/961942 [patent_app_country] => US [patent_app_date] => 2019-01-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15570 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -32 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16961942 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17371363 [patent_doc_number] => 20220026415 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-27 [patent_title] => A METHOD FOR SCREENING A THERAPEUTIC AGENT FOR CANCER USING BINDING INHIBITOR OF CYCLIN-DEPENDENT KINASE 1 (CDK1)-CYCLIN B1 AND RETINOIC ACID RECEPTOR RESPONDER 1 (RARRES1) GENE KNOCKOUT ANIMAL MODEL [patent_app_type] => utility [patent_app_number] => 17/296922 [patent_app_country] => US [patent_app_date] => 2018-12-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24897 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17296922 [rel_patent_id] =>[rel_patent_doc_number] =>)